Introduction
Cellular homeostasis is a process regulated by an integrative and coordinated balance among differentiation, proliferation and apoptosis. Alterations to this complex circuitry can lead to progressive conversion of normal cells into prototypic cancer cells, which are characterized by deregulated (i.e., autonomous) cell growth. Results from biochemical and genetic studies have revealed that members of the non-receptor tyrosine kinases, such as the Btk/Tec family, play a pivotal role in the regulation of cellular responses and gene expression (Ekman et al., 1997; Qiu et al., 1998; Tamagnone et al., 1994; Tsai et al., 2000) .
Members of this kinase family consist of Btk, Itk, Tec, and Etk/Bmx (reviewed in Qiu and Kung, 2000) , which share conserved structural motifs including an N-terminal pleckstrin homology (PH) domain, followed by Src homology 3 (SH3) and 2 (SH2), and a carboxyl-terminal tyrosine kinase domain. While Btk/ Tec family kinases are preferentially expressed in hematopoietic cells and have lineage-specific functions, Etk/Bmx is expressed in epithelial, endothelial, and granulomonocytic cells (Qiu et al., 1998; Tamagnone et al., 1994) . Etk activation was reported to be involved in Src-mediated cell transformation (Tsai et al., 2000) and IL-6 induced neuroendocrine differentiation of prostate cells (Qiu et al., 1998) . Several lines of evidence have implicated Btk family members in modulating apoptosis pathways under different experi-mental paradigms. For example, overexpression of Etk renders LNCaP cells more resistant to photodynamic therapy-or thapsigargin-induced apoptosis (Xue et al., 1999) , whereas Etk sensitizes mast cell line 32D toward apoptosis upon treatment with G-CSF (Ekman et al., 2000) . Wu et al. (2001) have demonstrated that Etk is an enzyme substrate for caspase 3 during apoptosis, implicating that Etk may serve as an apoptotic switch. Recently, results from experiments using transient transfection in MCF-7 and MDA-MB435 cells suggested that Etk enhances the proliferation and anchorage-independent, tumorigenic growth of mammary epithelium-derived cells (Bagheri-Yarmand et al., 2001) . In addition, our laboratory has demonstrated that Etk activation renders hypoxia resistance to Pa-4 cells by preserving their epithelial tight junctions and barrier function during chronic hypoxic exposure (Hamm-Alvarez et al., 2001) . Together, these data are consistent with a thesis that Etk/Bmx activation is involved in the cytoprotection and adaptive responses against environmental cues. However, the precise mechanism of how Etk assumes such an essential role in the modulation of signal pathways underlying cell survival and growth or evading apoptosis remains to be elucidated.
Cytokines and growth factors have also been shown to mediate many aspects of multicellular communications. Among them, vascular endothelial growth factor (VEGF) is particularly adept in evoking an extremely broad spectrum of biological responses (Ferrara, 1999) . For example, increased VEGF levels are associated with stimulating cell proliferation, inducing cell migration, promoting cell survival, and regulating physiological and pathological angiogenesis (Neufeld et al., 1999; Veikkola and Alitalo, 1999) . The angiogenic action of VEGF involves an anti-apoptotic effect that promotes endothelial cell proliferation, mediated through its tyrosine kinase receptor, Flk-1/ KDR/VEGFR-2, and the PI3-K/Akt signaling cascade (Gerber et al., 1998a,b) . Moreover, VEGF was found to stimulate DNA synthesis of endothelial cells preferentially through the same receptor, activating a distinct ERK1/2 pathway (Kanno et al., 2000) , which was considered indispensable for the survival of endothelial cells (Gupta et al., 1999) . Furthermore, these observations have recently been extended to renal tubular epithelial cells, suggesting that VEGF also promotes the survival of certain epithelial cells (Kanellis et al., 2000) . Consequently, alterations in the expression and activity of VEGF have been postulated to play a crucial role in acquisition of the migrating and invasive tumorigenic properties of human malignant cells (Bagheri-Yarmand et al., 2001) .
Mechanisms underlying the induction of VEGF expression involve multiple signaling pathways that are rather complex and not clearly understood. Transcriptional regulators for VEGF include cytokines, growth factors, oncogenes (Grugel et al., 1995; Rak et al., 1995) and hypoxia (Shweiki et al., 1992) , acting through either Src (Mukhopadhyay et al., 1995) or PI3-K signaling cascade (Jiang et al., 2000) . While the induction of VEGF expression under hypoxic conditions is mainly mediated by the hypoxia response element (HRE)/hypoxia inducible factor-1 (HIF-1) (Forsythe et al., 1996; Ryan et al., 1998) , the transcriptional hierarchy governing VEGF expression during normoxia is only partially delineated. Because Etk enhances cell survival and overexpression of both VEGF and Etk are involved in tumor cell progression (Bagheri-Yarmand et al., 2001; Ferrara, 1999) , we hypothesize that VEGF may be a downstream target gene of the Etk signaling pathway. Moreover, as upregulation of VEGF expression by PI3-K (Jiang et al., 2000) promotes cell survival and tumor growth (Blume-Jensen et al., 1998; Murakami et al., 1999; Shaw, 2001; Toker and Cantley, 1997; Vanhaesebroeck and Alessi, 2000; Zheng et al., 2000) in hypoxia, we also postulate that PI3-K might also provide a link between the Etk signaling cascade and VEGF gene regulation under normoxia. Since VEGF governs cell survival through activation of a distinct ERK1/2 pathway (Kanno et al., 2000) and previous studies from our laboratory demonstrated that Etk activation is sufficient to stimulate ERK1/2 kinases , we further propose that ERK1/2 provides an additional link between Etk and VEGF. Taken together, Etk may utilize both ERK and PI3-K signaling pathways, acting in concert, to stimulate VEGF expression via an HRE-independent transcriptional activation of the VEGF promoter.
Additionally, recent studies have suggested VEGF to be an autocrine growth factor in various tumor cell lines that express both VEGF and its receptor (Dias et al., 2002; Masood et al., 2001; Strizzi et al., 2001) . However, the mechanism underlying this observation has yet to be established. Since our endothelial model, TR-BBBDEtk : ER, exhibits both properties, we also predict that the enhancement in survival and proliferation of endothelial cells occurs, at least in part, as a consequence of an autocrine mechanism via the activation of endogenous Etk by Etk-stimulated VEGF expression. In this study, we provide direct evidence that Etk activation alone is sufficient to promote the expression of endogenous VEGF in both epithelial and endothelial cells, contributing to their subsequent phenotypic manifestations via a reciprocal feedforward mechanism.
Results

Induction of VEGF expression by Etk activation in Pa-4DEtk : ER cells
We have previously reported that Etk activation is able to provide cytoprotection against hypoxia in Pa4DEtk : ER cells overexpressing an estradiol-inducible form of Etk, DEtk : ER (Hamm-Alvarez et al., 2001) . However, the specific signaling pathway and downstream target genes activated by Etk are still elusive. Since VEGF has been shown to be a survival factor for epithelial cells (Kanellis et al., 2000) and is also upregulated by hypoxia (Jiang et al., 2000) , we examined herein whether VEGF could be an Etk downstream target gene and whether Etk is involved in the signaling cascade that leads to the activation of VEGF expression in both normoxia and hypoxia conditions. Hence, Northern blot analyses were performed on total RNAs prepared from Pa-4 and Pa-4DEtk : ER cells. The steady-state level of VEGF mRNA in Pa-4DEtk : ER cells was substantially higher than that detected in the parental Pa-4 cells under normoxia; however, this was to a lesser extent when compared to hypoxia (Figure 1a , lane 5 vs lanes 1 and 2, respectively). As expected, hypoxia and Etk activation together induced a much higher steady-state level of VEGF mRNA than that detected under either Etk activation or hypoxia alone (Figure 1a , lane 6 vs lanes 5 and 2, respectively).
We then sought to use pharmacological reagents to explore the role of Etk in modulating VEGF expression under both experimental paradigms. LFM-A13, a leflunomide metabolite analog, has been reported to be a selective inhibitor of Btk, but a poor inhibitor of EGFR, Hck, JAK1, JAK3A, and IRK . The reported IC 50 values for EGFR, insulin receptor, JAK1, JAK2, JAK3A, Syk, Hck are all 110-fold higher than the IC 50 determined for the recombinant Btk (Vassilev et al., 1999) . Since Etk is closely related to Btk and belongs to the same family of cytoplasmic protein tyrosine kinases, we tested the possibility that LFM-A13 is capable of attenuating Etk activity. As shown in Figure 1b , LFM-A13-treatment inhibited Etk tyrosine phosphorylation in a dose-dependent manner (lanes 2 and 3 vs lane 1). We then examined the effect of LFM-A13 treatment on VEGF expression in the parental and Etk-activated Pa-4 epithelial cells. In addition, since the PI3-K pathway activation has been demonstrated to augment VEGF expression under hypoxia (Jiang et al., 2000) , Wortmannin, a PI3-K inhibitor, was used as a positive control. The steady-state b-actin mRNA levels were used to assure the quality and quantity of mRNAs loaded onto each lane and the relative specificity of individual experimental paradigms. As shown in Figure  1a , both Wortmannin and LFM-A13 treatments rendered a marked attenuation of hypoxia-induced VEGF induction in Etk-activated cells (lanes 7 and 8 vs lane 6). The downregulation of VEGF induction by the same treatments, to a lesser extent, was also observed in the parental Pa-4 cells under hypoxic condition (Figure 1a , lanes 3 and 4 vs lane 2), implicating that both PI3-K and endogenous Etk pathways might also be involved, following hypoxia. Together, we hypothesize that the increase in steady-state levels of VEGF expression can be achieved by a combined Etk-and hypoxia-dependent mechanism. Since Etk augments VEGF expression regardless of hypoxia, we herein focused our efforts on delineating the Etk-dependent pathways involved in VEGF gene regulation and investigating the role of Etk activation in governing cellular processes under normoxia.
Etk induces VEGF transcription via a HRE-independent mechanism
Next, we directly determined whether Etk utilizes a hypoxia response element (HRE)-dependent and/or -independent mechanism to upregulate VEGF expression at the transcriptional level under normoxia. A series of 5'-VEGF promoter/enhancer deletion reporter constructs were engineered and examined by transient transfection assays (Figure 2 ). We first confirmed that a HRE-dependent pathway is operative in our cells, evident from the fact that transfected HIF-1a/1b supports hypoxia-mediated 71.2VEGF-luc induction (Chau CH and Ann DK unpublished observation). The relative abilities of these individually transfected VEGF-reporter constructs to be stimulated by Etk under normoxia were then analysed and compared in order to determine the DNA region required for inducing VEGF expression by Etk signaling under normoxia. As shown in Figure 2b , the DNA sequences within the (71175/7790) DNA fragment were clearly dispensable for Etk-mediated VEGF promoter activation (constructs I and IV vs constructs II and V, respectively), supporting the notion that Etk utilizes an HRE-independent mechanism to potentiate VEGF In order to ascertain that this VEGF-reporter induction is indeed mediated by Etk activation alone, we co-transfected Pa-4DEtk : ER cells with either 71.2VEGF-luc or 70.13VEGF-luc and a dominant negative kinase-dead Etk expression construct, Etk KQ . Etk KQ harbors a point mutation (K445Q) in its ATP binding pocket, rendering the loss of its kinase activity (Jui et al., 2000) . As shown in Figure 2c , cotransfection with Etk KQ resulted in a substantial inhibition of Etk-stimulated VEGF-reporter activation under normoxia. Taken together, our results clearly provide the first demonstration that Etk activation alone is capable of upregulating VEGF expression at the transcriptional level via an HRE-independent mechanism in normoxia.
Activation of VEGF enhancer/promoter activity by Etk is conferred via both ERK and PI3-K pathways
In order to delineate Etk-mediated downstream signaling events that stimulate VEGF promoter/ enhancer activity, transient transfections assays with The luciferase assays and data analyses were carried out as described in Materials and methods. Each value shown is the mean+s.d. based on at least three independent transfection experiments reporter constructs devoid of the aforementioned HRE were utilized. To further confirm that Etk activation is absolutely required for inducing VEGF expression in normoxia, Pa-4DEtk : ER cells were transiently transfected with reporter constructs, 70.79VEGF-luc and 70.13VEGF-luc, followed by Etk stimulation in the presence or absence of LFM-A13, (Figure 1b ), prior to luciferase assays. As expected, Etk activation resulted in approximately 9.7-and 4.1-fold inductions over their respective basal activities ( Figure 3a , lane 2 vs lane 1).
Treatment with 50 or 100 mM LFM-A13 attenuated the Etk-mediated VEGF-promoter induction in a dosedependent manner (Figure 3a , lanes 4 and 5 vs lane 2), consistent with the observation in Figure 1a that LFM-A13 treatment downregulates VEGF expression.
Since Etk activates the ERK pathway , we also investigated the contribution of the ERK pathway to VEGF expression using Ras expression plasmids and appropriate pharmacological agents. First, expression plasmids encoding a constitu- Figure 3 Stimulation of VEGF enhancer/promoter activity by Etk is conferred via both ERK and PI3-K pathways in two distinct DNA regions. (a) Reporter constructs II and IV (see Figure 2) were transiently co-transfected with expression plasmids encoding either a constitutively active Ras (Ras V12) or PI3-K (myr-p110), a dominant negative Ras (Ras A15), p21 activated kinase (Pak1 DN ), or Etk KQ ; or treated with pharmacological agents U0126 (10 or 50 mM), LFM-A13 (50 or 100 mM), or LY 294002 (10 mM) for 16 h. The luciferase assays and data analyses were carried out as described in Figure 2 . (b) Immunoprecipitation with anti-ER and Western analyses with either the 4G10 (anti-Tyr(P)) or an anti-ER were performed as described in Figure 1b on cells treated with vehicle, E 2 alone, E 2 +10 mM LY 294002, E 2 +100 nM Wortmannin, and E 2 +50 mM U0126, respectively. These experiments have been repeated at least three times with comparable results. One representative Western analysis is shown tively activated Ras, Ras V12, or a dominant negative Ras, Ras A15, were transiently co-transfected with 70.79VEGF-luc or 70.13VEGF-luc reporter constructs to test whether Ras/ERK pathway is utilized by Etk to modulate VEGF expression. As shown in Figure 3a , our results clearly demonstrated that cotransfection with the constitutively activated Ras V12 recapitulated Etk-dependent 70.79VEGF-luc activation, albeit to a lesser extent (4.6-fold induction vs 9.7-fold induction; lane 6 vs lanes 1 and 2). By contrast, Ras V12-mediated pathway was sufficient to mimic Etk for 70.13VEGF-luc activation. Moreover, this Etkmediated activation was inhibited by co-expression of the dominant negative Ras A15 (Figure 3a, lane 7) . Thus, Etk-mediated enhancement of VEGF expression occurs, at least in part, via stimulating Ras-dependent signaling pathways. Ras V12 was less efficacious in stimulating 70.79VEGF-luc reporter, suggesting that a Ras-independent signaling pathway via the (7790/ 7131) region is also critical for mediating VEGF transcriptional activation upon Etk stimulation. We further determined whether the activation of MEK is required for Ras-dependent VEGF induction by Etk. The pharmacological inhibitor U0126 was chosen, as it inhibits MEK1/2 directly by blocking its catalytic activity (Favata et al., 1998) . Clearly, treatment with 10 or 50 mM U0126 of Etk-activated and 70.13VEGF-luc transfected cells resulted in a complete repression of VEGF promoter activities (Figure 3a, lanes 8 and 9) . Therefore, activation of the MEK/ERK pathway is a necessary step for the transcriptional regulation of VEGF by Etk. However, inhibition of MEK activation, even with 50 mM U0126, did not completely abolish the Etk-mediated 70.79VEGF-luc induction, implicating the involvement of at least one additional pathway other than MEK/ERK, activated by Etk to regulate VEGF expression via the (7790/7131) region.
Since Ras is also known to stimulate intracellular signaling via the PI3-K pathway, we next determined whether PI3-K activation is also involved in this Etkdependent signaling cascade. We used LY 294002, a more selective PI3-K inhibitor than Wortmannin, to inhibit PI3-K activity in our transient transfection assays. Treatment with this inhibitor of 70.79VEGF-luc transfected cells resulted in a dose-dependent (data not shown) reduction of Etk-mediated 70.79VEGF-luc reporter activation. To further ascertain that the PI3-K pathway is involved in the induction of VEGF by Etk, we co-transfected 70.79VEGF-luc and 70.13VEGF-luc with an expression construct, myrp110, harboring constitutively activated PI3-K. Ectopic expression of the myr-p110 subunit in Pa-4 cells resulted in a substantial enhancement of the Etkstimulated 70.79VEGF-luc activity, but not the Etkstimulated 70.13VEGF-luc reporter activity ( Figure  3a , lane 10). Pretreatment of myr-p110 co-transfected cells with 10 mM LY 294002 had an inhibitory effect on Etk/p110-stimulated activities of 70.79VEGF-luc, while this combined regimen had little effect on the induction of 70.13VEGF-luc (Figure 3a, lane 11) . Coexpression of the Pak1 DN (a dominant negative p21 activated kinase), a downstream effector of PI3-K, led to the attenuation of Etk-stimulated 70.79VEGF-luc activation, but not 70.13VEGF-luc activation ( Figure  3a , lane 12 vs lane 2). The activation of PI3-K clearly rendered VEGF transcriptional activation via the (7790/7131), but not the (7131/+336), region. The lack of effect by co-transfected myr-p110 or Pak1 DN , and by LY 294002 pretreatment on the activities of 70.13VEGF-luc served as a negative control, demonstrating the specificity of individual signaling pathways on distinct regions located within the VEGF promoter/ enhancer. This observation provided a direct link between PI3-K/Pak1 activation and Etk-mediated VEGF induction. To rule out the possibility that PI3-K or MEK/ERK pathway acts upstream of Etk activation, we investigated whether LY 294002, Wortmannin, or U0126 interferes with Etk activation. As illustrated in Figure 3b , the pretreatment of each inhibitor had very little, if any, effect on DEtk : ER activation. Taken together, our results conceivably suggest that both PI3-K/Pak and MEK/ERK pathways are the downstream effectors of Etk, albeit via different DNA motifs, in modulating the transcriptional upregulation of VEGF expression under normoxic condition. Based on these observations, we propose that there are at least two distinct upstream and downstream Etk response regions, independent of HRE, acting in concert to modulate VEGF expression under normoxia (see Discussion for details).
Etk induces VEGF expression in endothelial cells and enhances cellular differentiation on matrigel
Since Etk is also expressed in endothelial cells and VEGF is a known endothelial cell mitogen, we examined the biological effect of Etk activation on endothelial cellular processes. To achieve this, rat blood-brain-barrier microvascular endothelial TR-BBB cells (Terasaki and Hosoya, 2001) were stably transfected with a DEtk : ER expression construct. A clone (clone 4) exhibiting the highest DEtk : ER activation upon ER stimulation, as assessed by Western analyses with an anti-Tyr(P) antibody (data not shown), was selected for further studies and hereafter referred to as TR-BBBDEtk : ER cells.
To ascertain if the Etk-mediated signaling pathways that we demonstrated above in epithelial Pa-4 cells also dictate overall VEGF expression level in endothelial cells, we assessed the effect of Etk on VEGF promoter/ enhancer activity using transient transfection and reporter assays carried out in TR-BBBDEtk : ER cells. As illustrated in Figure 4a , Etk activation in TR-BBB cells also markedly induced the expression of transfected 71.2VEGF-luc and 70.79VEGF-luc reporters, while a very modest induction on the transfected 70.13VEGF-luc was elicited by Etk. Thus, the HRE is also not required for Etk-mediated VEGF induction under normoxia in endothelial cells. Furthermore, a dominant negative form of Etk, Etk KQ , markedly repressed Etk-stimulated reporter activation when co-transfected in TR-BBB cells. These observations in microvascular TR-BBB cells are reminiscent of the identification of Etk as a positive stimulator of VEGF gene expression via a HRE-independent mechanism in epithelial cells, as shown Figures 1 and 2 . Hence, we conclude that Etk could function to induce VEGF expression in an analogous fashion in endothelial cells to that in epithelial cells.
Since VEGF is known to stimulate angiogenesis in vivo, we tested the ability of Etk to promote in vitro formation of capillary-like networks on Matrigel, a protein substratum mixture that supports the organization of endothelial cells into tubes. To examine whether Etk enhances the differentiation of endothelial cells on the basement membrane, we plated parental TR-BBB and TR-BBBDEtk : ER cells on growth factor-reduced Matrigel. All cells were incubated in the absence of exogenous growth factors, serum, or phenol red. As shown in Figure 4b , TR-BBBDEtk : ER cells formed much more elaborate, branching, cord-like capillary networks at 9 h post-plating of cells than the parental TR-BBB cells. Thus, TR-BBBDEtk : ER cells retained their endothelial characteristics of forming the intricate capillary network on Matrigel at a faster rate and to a greater extent than the parental TR-BBB cells, most likely due to its Etk activation. ER cells were plated on growth factor-reduced Matrigel in the absence of exogenous growth factors, serum, or phenol red for 9 h. Cells were photographed and assessed at 106 magnification using phase microscopy. Five random fields were examined and the experiment was repeated twice additionally
Etk promotes the survival and proliferation of endothelial cells via an autocrine mechanism
To confirm the role of VEGF and Etk in promoting proliferation and survival of TR-BBBDEtk : ER cells, two antisense oligonucleotides, AS-3 (anti-VEGF) (Masood et al., 2001 ) and anti-Etk (Chen et al., 2001) , were utilized to downregulate the expression of VEGF and Etk, respectively. These two antisense oligonucleotides have previously been tested extensively for its specificity against their respective targets and demonstrated to be effective reagents in many cell types (Chen et al., 2001) . As shown in Figure 5a ,b, TRBBBDEtk : ER cells exhibited a more cuboidal morphology compared to the spindle shape of the prototypical microvascular cell. Treatment of TRBBBDEtk : ER cells with any of these two antisense oligonucleotides exhibited a marked growth inhibitory effect (Figure 5d ,e vs 5c), while a lesser effect was observed on parental TR-BBB cells (data not shown). Western analyses were performed to assure the validity of our antisense approach. As shown in Figure 5d ,e, anti-VEGF substantially attenuated VEGF expression, while anti-Etk elicited a less pronounced effect on endogenous Etk level and no effect on DEtk : ER transgene expression in TR-BBBDEtk : ER cells. The lack of robust inhibition on endogenous Etk expression by anti-Etk may be due to the degradation of the antisense oligonucleotides during our prolonged 48 h incubation time in a gene-specific and cell contextdependent manner. Together, it is conceivable to propose that the endogenous VEGF/Etk expression is involved in maintaining the survival of these cells. As we have shown that Etk upregulates VEGF expression and promotes the proliferation of endothelial cells, we postulate that this enhanced proliferative state might occur via a positive feedforward mechanism, i.e., a reciprocal VEGF-induced activation of endogenous Etk is in place. To examine the effect of VEGF on Etk, it is necessary to first determine if these cells express VEGF receptors. Hence, Western analysis was performed on total cell lysates to indicate the presence of the VEGF receptor, Flk-1/KDR/VEGFR-2, as shown in Figure 5f .
In order to test the hypothesis that Etk increases the production of VEGF, which subsequently binds to its receptor after secretion into the culture media, leading to the increased survival and enhanced cellular processes of these cells, cultured HUVECs, known to express Flk-1/KDR/VEGFR-2 (Kanno et al., 2000) and Etk, were treated with 20 ng/ml VEGF and assayed for Etk activation. As Etk activation is known to lead to its own tyrosine autophosphorylation (Jui et al., 2000; Wen et al., 1999) , we also examined whether VEGF treatment results in a change in the tyrosine phosphorylation of Etk. For this, Etk was immunoprecipitated by anti-Etk antibody from lysates prepared at various time intervals post-treatment, followed by Western analysis with an anti-Tyr(P) antibody to detect Etk activation, while an anti-Etk antibody was used independently to demonstrate the comparable loading of protein samples. As illustrated in Figure 6 , VEGF treatment alone was sufficient to induce tyrosine phosphorylation of Etk within 30 min following VEGF treatment and further elevation was observed with a longer exposure of HUVECs to VEGF. Taken together, these results clearly establish that VEGF induces Etk activation in endothelial cells and the signal transduction pathway mediated by Etk is indeed indispensable for rendering the enhanced survival of these cells.
Discussion
This report, for the first time, provides evidence that the transcription of VEGF, an important mitogen and survival factor for both epithelial and endothelial cells, is directly induced by Etk activation. The subsequent secretion of VEGF and binding to its receptor in an autocrine fashion are able to further activate Etk, ultimately rendering an autoregulatory loop to reinforce its effect on cellular processes. We have identified Etk as one of the major key regulators in governing epithelial/endothelial cell proliferation and survival. Such an autocrine manner of promoting cell survival by VEGF has recently been investigated by several groups (Dias et al., 2001; Dunk and Ahmed, 2001; Masood et al., 2001; Vega-Diaz et al., 2001) . However, our data on the reciprocal stimulation between Etk activation and VEGF induction represent the first demonstration, to our knowledge, on the roles of signaling pathways utilized by Etk in the transcriptional control of the VEGF gene and its subsequent biological responses, especially in normoxia.
We elucidated the mechanisms by which Etk/Bmx achieves specific transcriptional induction of endogenous chromosomal genes, in particular VEGF, to stimulate cell growth and survival by examining the roles of individual pathways of Etk, MEK/ERK, and PI3-K/Pak1 signaling and their cross-talk in the induction of VEGF expression and activation of its downstream effector. The major findings of the present study are as follows: (1) Etk activation alone, utilizing a HRE-independent mechanism, is capable of inducing VEGF expression at the transcriptional level in both epithelial and endothelial cells under normoxia (Figures 1a, 2 , and 4a); (2) either LFM-A13, an inhibitor for Btk/Tec tyrosine kinase family members, or a dominant negative form of Etk, Etk KQ , inhibits the Etk-dependent induction of VEGF promoter/ enhancer activation (Figures 1a and 3a) , consistent with Etk-mediated upregulation of VEGF expression in normoxia; (3) both MEK/ERK and PI3-K/Pak1 signaling pathways are utilized by Etk, acting in concert to activate VEGF transcription ( Figures 3  and 4a) ; (4) Etk activation also markedly potentiates their ability to form capillary networks in vitro ( Figure  4b) ; (5) exogenous addition of antisense oligonucleotides against VEGF or Etk results in a dramatic inhibition of proliferation of these endothelial cells ( Figure 5d ,e); and (6) treatment with exogenous VEGF activates endogenous Etk in human endothelial HUVECs (Figure 6 ). These data taken together suggest a feedforward mechanism to reinforce Etk-mediated signaling events, providing direct evidence that there is an auto-regulation dictating the reinforcement between Etk activation and the upregulation of VEGF expression, ultimately leading to the observed phenotypic manifestations.
We purposely set out to determine the mechanisms utilized by Etk under the non-hypoxic condition to induce VEGF expression in both epithelial Pa4DEtk : ER and microvascular TR-BBBDEtk : ER cells. Previous studies by others have shown the major role that HIF-1 plays in VEGF expression and angiogenesis in hypoxia (Forsythe et al., 1996; Ryan et al., 1998) . While hypoxia remains the undisputed, ubiquitous inducer for VEGF expression, our results suggest that activation of other signaling pathways, such as Etk, also increases VEGF expression in normoxia to constitute a novel and additional regulatory network, providing a timely and precise modulation of a variety of physiological and pathological responses. Recently, Bagheri-Yarmand et al. (2001) reported that Etk activation enhances the proliferation, anchorage-independent growth, and tumorigenicity of human breast cancer cells; however, the precise mechanism by which Etk exerts its profound stimulatory effect on cancer cells is still elusive. We believe that our studies reported herein provide the first mechanistic evidence to potentially link Etk activation/VEGF upregulation and increased cancer cell activity in vitro and in vivo, as an underlying mechanism.
As illustrated in Figure 7 , our results suggest that: (1) Etk activation and hypoxia may function through at least two distinct, Etk-dependent and HREdependent, pathways to stimulate VEGF expression; (2) MEK/ERK and PI3-K, two Ras downstream signaling pathways, and a to-be-identified Ras-independent signaling pathway are all utilized by Etk to mediate the VEGF induction; (3) while MEK/ERK exerts its inducibility via both upstream and downstream Etk response regions, PI3-K/Pak1 and Rasindependent pathways activate VEGF promoter via the upstream region exclusively; (4) the induced secretion of VEGF not only promotes cell proliferation and survival, but also activates Etk-mediated signaling events further. Based on the results presented herein, we conclude that both VEGF and Etk are involved in an auto-regulatory loop that enhances cellular processes and biological responses in both epithelial and endothelial cells, such as cell proliferation and capillary-like tube formation on growth factor-reduced Matrigel.
We would like to point out that Etk regulation of VEGF gene expression seems to be more dependent on the MEK/ERK pathway, since inhibition of MEK1/2 with U0126 completely abrogated 70.13VEGF-luc induction, while reducing 70.79VEGF-luc induction by more than 65%. PI3-K, on the other hand, appears to play a somewhat lesser role, since treatment with a pharmacological inhibitor of PI3-K led to about 30% reduction in the stimulated 70.79VEGF-luc activities (Figure 3a) . Although stimulation of the PI3-K pathway plays a less prominent role, regulation of VEGF by PI3-K may be independent of MEK/ERK, since they appear to function in an additive manner ( Figure  3a) . Moreover, Etk-dependent VEGF induction can be achieved via both Ras-dependent and -independent mechanisms, since Ras V12 does not exactly reproduce the fold-induction achieved by Etk activation, and Ras A15 does not completely ameliorate Etk-mediated inducibility, either (Figure 3a) . A direct role for the downstream effector(s) of Ras-independent pathway in the activation of VEGF expression, however, has yet to be determined. It is also possible that in addition to these identified effectors, there are other unidentified Etk downstream effectors that contribute to the observed phenotypic changes. While the mechanism to accomplish Etk-mediated VEGF induction in endothelial cells could be different from those identified in epithelial cells, as cellular contexts may impart different specificity on the VEGF promoter/enhancer, we have unequivocally demonstrated that Etk activation alone is sufficient to induce both 71.2VEGF-luc and 70.79VEGF-luc activities in TR-BBB cells ( Figure  4a ). It should be pointed out, however, that the utilization of these proposed Etk-mediated pathways by hypoxia also remains to be established.
Considerable evidence from previous reports has established that VEGF signaling through Flk-1/KDR/ VEGFR-2 or Flt-1/VEGFR1 induces activation of ERK1/2, p38 MAPK, Akt, phospholipase Cg, and focal adhesion kinase (Abedi and Zachary, 1997; Gerber et al., 1998b; Kroll and Waltenberger, 1997; Mao et al., 2001; Wu et al., 2000) . While focal adhesion kinase is associated with cell migration (Lu (Parrizas et al., 1997) . Moreover, ERK1/2 activation also promotes endothelial cell proliferation and morphological changes (Gotoh et al., 1999; Wu et al., 2000) . Our results further implicate that Etk has an anti-apoptotic/pro-proliferative role in endothelial cells (Figure 6 ). The expression of Flk-1/ KDR/VEGFR-2 is abundant in proliferating endothelial cells of embryonic vascular sprouts and early postnatal brain, but is reduced in adult brains (Millauer et al., 1993) . Together with the data of Flk-1/ KDR/VEGFR-2 being present in TR-BBB cells and HUVEC (this report and Zeng et al., 2001) , it is conceivable to conclude that Etk induces VEGF expression and that subsequently the secreted VEGF binds to Flk-1/KDR/VEGFR-2 to modulate endothelial cellular processes in an autocrine manner. Studies with Etk/Bmx knockout mice demonstrated that Etk/ Bmx-null mice are viable and without an obvious phenotype, at least in the context of DBA/2 background (Rajantie et al., 2001) . Although this observation suggests that Etk-mediated signaling may be a redundant pathway, it does not rule out the possibility that enhanced Etk-dependent signaling exerts a positive modulatory effect on various cell behaviors, rendering adaptive responses to noxious environment. Taken together, our results clearly support the notion that Etk-dependent signal transduction and Etk-induced VEGF regulation have physiological and/or pathophysiological relevance, in the context of an autocrine-based mechanism.
In conclusion, the data from our current studies suggest that both Etk and VEGF are involved in an autocrine regulatory loop, which plays an important role in governing cell proliferation and cellular adaptive responses. Moreover, our results presented herein constitute the first direct evidence that Etk activation alone, independent of hypoxia, is sufficient to stimulate VEGF expression, utilizing both PI3-K/ Pak1 and ERK pathways. Hence, Etk activation is likely to be necessary for modulating these and other various cellular processes. Understanding the signaling pathways mediated by Etk for the activation of VEGF expression and the design of novel inhibitor molecules effective against Etk and Etk-dependent cascades to disrupt this autoregulatory loop may have important implications in tumor progression, metastasis and angiogenesis.
Materials and methods
Cell culture
The rat parotid epithelial cell line, Pa-4, was plated on Primaria culture dishes (BD Labware, Franklin Lakes, NJ, USA) in Dulbecco's modified Eagle's/Ham's F12 (1 : 1) medium (DMEM/F12), supplemented with 2.5% fetal bovine serum, insulin (5 mg/ml), transferrin (5 mg/ml), epidermal growth factor (25 ng/ml), hydrocortisone (1.1 mM), glutamate (5 mM), and kanamycin monosulfate (60 mg/ml), and maintained in a humidified atmosphere of 5% CO 2 and 95% air at 358C. Pa-4DEtk : ER cells were established and cultured as described previously (Wen et al., 1999) . The conditionally immortalized rat brain microvascular endothelial cells, TR-BBB (Terasaki and Hosoya, 2001) , were plated on type I collagen-coated dish or flask in DMEM/F12 (1 : 1) medium (supplemented with 10% fetal bovine serum, endothelial cell growth factor (15 mg/ml), glutamate (5 mM), and kanamycin monosulfate (60 mg/ml), and maintained in a humidified atmosphere of 5% CO 2 and 95% air at 338C. For establishing TR-BBBDEtk : ER cells, TR-BBB cells were transfected with pLNCX-DEtk : ER construct (Wen et al., 1999) by the lipofectAMINE TM 2000-mediated method according to the standard procedure suggested by the manufacturer (Invitrogen Corporation -Life Technologies, Carlsbad, CA, USA) and selected with G418 (800 mg/ml) for neomycin resistant colonies. Different colonies of stably transfected TR-BBBDEtk : ER cells were isolated by limiting dilution. The expression and activation of DEtk : ER in TRBBBDEtk : ER cells were evaluated by Western analyses of cell lysates using an anti-ER antibody or sodiumdodecylsulfate-polyacrylamide gel electrophoresis (SDS -PAGE) of immunoprecipitates using an appropriate antibody.
Plasmid constructs, transient transfections and antisense treatment
All the VEGF-reporter constructs used in transient transfection assays contain sequences derived from the human VEGF gene (Tischer et al., 1991) . A SacI -SacI fragment (1511 bp) from the human VEGF gene, including 1175 bp of the promoter/enhancer region upstream of the transcription initiation site and 336 bp of the 5'-untranslated region was PCR-amplified and cloned in a sense orientation into the SacI site of pGL2-basic, to create 71.2VEGF-luc (Figure 2 One-tenth mg of the Renilla luciferase pRL-TK plasmid was co-transfected as an indicator for normalization of transfection efficiency. Six hours after the start of transfection, cells were recovered overnight in 0.1% serum-stripped medium and subsequently treated with vehicle (-Etk) or 1 mM bestradiol (E 2 ) to activate DEtk : ER (+Etk). Cells were treated for 16 h, before harvesting cell lysates for luciferase assays. The relative luciferase activity from the fireflyluciferase reporter gene was determined and normalized with Renilla-luciferase activity using the Dual Luciferase Reporter Assay System (Promega). All fold-induction data reported in this manuscript were calculated after normalizing the reporter activities with the activities from the indicator plasmid. In general, there was no obvious change on the basal activity in our co-transfection and inhibitor studies. Sometimes, a particular treatment may elicit a modulating effect on the general transcriptional machinery; however, these general effects were taken into account after the normalization with the activities of the indicator plasmid.
A comparable number (*10 000) of TR-BBB or TRBBBDEtk : ER cells was seeded in 24-wells on Day 0. On Day 1, cells were treated with antisense oligonucleotides of either VEGF or Etk in serum-reduced (2.5% stripped FBS) medium, as described previously (Masood et al., 2001) . The treatment was repeated on Day 3. On Day 5, cells were fixed with paraformaldehyde and stained with Coommassie blue. Five random fields were photographed at 46 under the light microscope and the experiment was repeated twice additionally.
Western analysis and immunoprecipitation
TR-BBB and TR-BBBDEtk : ER cells were treated with 1 mM E 2 for 16 h and lysed with 16 loading buffer for SDS -PAGE. Approximately 20 mg of whole cell extract from each sample was subjected to SDS -PAGE on a 10% gel. The immunoblot analyses were carried out as described previously (Li et al., 1997) . Anti-VEGF, anti-Flk-1/KDR/VEGFR-2 and anti-Etk/Bmx antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and Cell Signaling Technology, Inc. (Beverly, MA, USA). For immunoprecipitation studies, cells were lysed in RIPA buffer containing 16PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mg/ml phenylmethylsulphonyl fluoride, 30 mg/ml aprotinin and 1 mM sodium orthovanadate. Subsequently, the endogenous Etk was precipitated from cell lysates with an anti-Etk/Bmx antibody as described previously (Li et al., 1997) , followed by immunoblot analyses using an anti-phosphotyrosine (anti-Tyr(P)) antibody (4G10, Upstate Biotechnology, Inc., Lake Placid, NY, USA). Human endothelial cells from umbilical veins (HUVEC), passages 2 -5, were cultured in Medium 199 supplemented with 16.6% fetal bovine serum, 14 U/ml heparan sulfate, 20 mg/ml endothelial cell growth supplement (ECGS, Upstate Biotechnology), and 2 mM L-glutamine. HUVEC was cultured for 48 -72 h to reach confluence and then starved for 6 h with Medium 199 supplemented with 1.5% FBS, 14 units/ml heparan sulfate and 2 mM L-glutamine. For VEGF stimulation, the cells were pretreated with 0.5 mM vanadate for 1 h, followed by adding 20 ng/ml of human recombinant VEGF165 (Sigma, St. Louis, MO, USA) to media for the indicated time periods and subjected to lysis with RIPA buffer supplemented with a cocktail of phosphatase and protease inhibitors.
Northern analysis
Pa-4 and Pa-4DEtk : ER cells were cultured in a regular medium prior to exposure to 20 or 1% O 2 for 4 h. Cells were exposed to either normoxic or hypoxic condition in 0.05% serum-stripped medium prior to total RNA isolation. RNA blots were prepared and hybridization was carried out with 32 P-labeled VEGF probe prepared from an isolated rat VEGF cDNA fragment (bases 1 -560). All blots, after stripping, were re-probed with 32 P-labeled rat b-actin cDNA probe to ensure that the quality and quantity of RNA between lanes were comparable. Blots were exposed to films at 7808C overnight.
Matrigel assays for capillary-like network formation TR-BBB or TR-BBBDEtk : ER cells were plated on growth factor-reduced Matrigel for 9 h at 338C. Cells were photographed and assessed at 106 magnification using phase microscopy. Five random fields were examined and the experiment was repeated twice.
Statistical analysis
Experiments were carried out in duplicate at least three times. Representative data from these three independent experiments were presented. Significance (P50.05) was determined relative to the corresponding control by Student's t-test. The reporter activity shown is the mean+s.d. based on at least three independent transfection experiments.
